Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Avalo Therapeutics ( (AVTX) ) is now available.
On June 5, 2025, Avalo Therapeutics entered into a new Sales Agreement with TD Securities to offer and sell up to $75 million in common stock shares. This agreement follows the termination of a previous agreement with Oppenheimer & Co., which was concluded on June 4, 2025, allowing Avalo to explore new market opportunities without incurring termination penalties.
The most recent analyst rating on (AVTX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.
Spark’s Take on AVTX Stock
According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.
The overall score is driven by Avalo Therapeutics’ significant financial challenges and negative valuation metrics, which are partially offset by positive corporate developments, including strategic management changes and promising product potential. Technical indicators suggest a bearish trend.
To see Spark’s full report on AVTX stock, click here.
More about Avalo Therapeutics
Avalo Therapeutics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of therapeutic solutions. The company primarily deals with the creation and sale of common stock shares as part of its financial strategies.
Average Trading Volume: 78,853
Technical Sentiment Signal: Strong Sell
Current Market Cap: $47.64M
Find detailed analytics on AVTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue